EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Amed Co., Ltd. (7575) fair value: what the stock is really worth

As of Jul 31, 2026: fair value of Amed Co., Ltd. TWD 13.41, price TWD 11.45, upside +17.1%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW · ISIN TW0007575B17

AC Thin data Sep 24, 2026

Amed Co., Ltd.

7575 · TWO

SpeculativeUpside exists, but weak quality makes the signal speculative.

✓Fair value 13.41 TWD · Undervalued (+17.1%)
!Quality 46/100
!Expensive Growth (revenue 5y +11.6 %/yr)
!Thin margins · 4.4% net margin (FY2025)
!Moderate debt · negative free cash flow
!Trails peers (3/11)
!Moderate moat 47/100
!Evidence only low, so the estimate is less certain
Watch Amed Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

69.76 TWD 10.05 TWD Fair Value 13.41 TWD Jun 2022 Jul 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

49‑month range 10.05 TWD – 69.76 TWD · fair‑value band 13.41 TWD – 17.43 TWD · the 11.45 TWD price screens below the 13.41 TWD fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Amed Co. in your weekly email

Every Wednesday you see whether Amed Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Amed Co., Ltd. engages in the research and development, manufacture, and trading of medical equipment in Taiwan. It offers wound care dressing products under the HERADERM brand name; negative pressure wound therapy systems that provides 24-hour oxygen supply to wounds under the Genadyne brand name; and wound treatment systems under the Natrox brand name.

Show more

Amed Co., Ltd. engages in the research and development, manufacture, and trading of medical equipment in Taiwan. It offers wound care dressing products under the HERADERM brand name; negative pressure wound therapy systems that provides 24-hour oxygen supply to wounds under the Genadyne brand name; and wound treatment systems under the Natrox brand name. The company also provides 7-day long-acting pain reliever injections under the Naldebain brand name. In addition, it offers pressure injectable implantable port kits under the POLYSITE brand; and universal linear cutting staplers under the easyEndo brand name. The company was founded in 2008 and is based in New Taipei City, Taiwan.

Stock analysis

Amed Co., Ltd. (7575) currently trades at 11.45 TWD, while our model-based Fair Value estimate is 13.41 TWD, implying the stock looks roughly 14.6% undervalued today.

Show more

Valuation

Bull case: the Dividend Discount group reads highest at a median of 37.81 TWD per share, and 14 of the 17 models we run sit above the 11.45 TWD price.

Bear case: the Asset-Based group reads lowest at 8.87 TWD, and 3 of the 17 models stay below the price. Evidence for this calculation is low.

Scenario range: 13.41 TWD (bear) to 17.43 TWD (bull), the price of 11.45 TWD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Amed Co., Ltd. reported revenue of 822M TWD in FY2025 versus 559M TWD in FY2021, a compound +10.1%/yr. Reported net income was 35.8M TWD in FY2025, compounding −7.9%/yr from FY2021.

Key figures

Market cap 344M TWD (≈ $10.8M) · P/E ratio 9.6 · P/S ratio 0.42 · EPS (TTM) 1.19 TWD · Net margin 4.4% · Return on assets (EBIT) 10.4% · Free cash flow −8.3M TWD · Net debt 454M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (medium confidence).

What moves the price

The share trades about 62% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at 17%, 7575 screens cheaper than that median.

Fair Value models

Bear 13.41 TWD Fair Value 13.41 TWD Bull 17.43 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.8998 TWD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income 11.27 TWD 12.25 TWD 13.99 TWD 76
EPV 7.34 TWD 9.60 TWD 11.55 TWD 74
Owner Earnings 15.33 TWD 31.75 TWD 58.78 TWD 72
All 17 models by family
DCF Models
Owner Earnings 15.33 TWD 31.75 TWD 58.78 TWD 72
Earnings-Based
Graham-Dodd 8.11 TWD 36.14 TWD 49.51 TWD 64
Lynch FV 9.39 TWD 13.41 TWD 17.43 TWD 61
PEG = 1.0 9.39 TWD 13.41 TWD 17.43 TWD 57
EPV 7.34 TWD 9.60 TWD 11.55 TWD 74
Dividend Discount
Gordon GGM 21.96 TWD 43.75 TWD 66.25 TWD 67
DDM Multi-Stage 21.96 TWD 37.81 TWD 46.18 TWD 67
Multiples
P/E Multiple 19.68 TWD 26.25 TWD 32.81 TWD 63
P/S Multiple 15.21 TWD 20.28 TWD 25.35 TWD 58
P/B Multiple 15.21 TWD 20.28 TWD 25.35 TWD 55
EV/EBIT 25.51 TWD 36.33 TWD 47.15 TWD 65
EV/EBITDA 33.58 TWD 47.09 TWD 60.60 TWD 67
EV/Revenue 16.21 TWD 26.14 TWD 36.08 TWD 53
Asset-Based
NCAV (Graham) 6.62 TWD 8.87 TWD 13.23 TWD 54
Economic Profit
Residual Income 11.27 TWD 12.25 TWD 13.99 TWD 76
ROIC Compounder 7.34 TWD 9.60 TWD 11.55 TWD 72
Growth Earnings
Growth-Adj P/E 15.76 TWD 22.51 TWD 29.27 TWD 67

Open the full fair value analysis →

Notify me when 7575 reaches fair value

Put 7575 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 46/100

Of which business quality 42 · Market factors (momentum, volatility) 7

Profitability 48
Margins and returns on capital today
Quality Growth 34
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 35
Balance sheet, leverage, solvency risk
Investment 69
Disciplined investing over empire-building
Low Volatility 18
Calm price path (market factor)
Momentum 1
Price trend over the last 3–12 months (market factor)
52W Momentum 3
Distance to the 52-week high (market factor)
Net Issuance 84
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 53/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+0.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.2%
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+5.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.8%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 9%

Watch 7575, get fair value alerts →

Compare Amed Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 185 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Bottom 25%
Fair Value upside +17.1% · Above median
Profitability
Return on assets 0.0% · Bottom 25%
Net margin (TTM) 4.4% · Below median
Operating margin (TTM) 0.0% · Bottom 25%
Growth and dividend
Revenue growth 0.0% · Below median
Dividend yield (TTM) 0.0% · Bottom 25%
Balance sheet
Debt / equity 0.72× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 9.6× · Cheapest 25%
EV/EBITDA 1.7× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)56 · sector 25
FUTURE (revenue growth)0 · sector 35
PAST (return on equity)0 · sector 28
HEALTH (low debt)64 · sector 96
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $406.63 $348.72 −14%
EssilorLuxottica Société anonyme EL €144.60 €159.06 +10%
Becton, Dickinson and Company BDX $178.07 $104.73 −41%
Medline Inc MDLN $34.70 $29.06 −16%
Alcon Inc ALC $63.94 $40.13 −37%
West Pharmaceutical Services, Inc WST $375.65 $137.81 −63%
Sartorius Stedim Biotech S.A DIM €208.20 €54.82 −74%
Straumann Holding STMN CHF 89.80 CHF 45.50 −49%
Sartorius Aktiengesellschaft SRT €206.50 €42.05 −80%
Solventum Corporation SOLV $89.50 $134.36 +50%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Amed Co., Ltd. · Fair Value
13.41 TWD +15%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Amed Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/7575

Frequently asked questions

Is Amed Co., Ltd. (7575) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 13.41 TWD versus the last price from Jul 31, 2026 of 11.45 TWD, about +17% upside (undervalued).
What is the fair value of 7575?
Our model-based fair value for Amed Co., Ltd. is 13.41 TWD (as of Sep 24, 2026), built from audited fundamentals. Last price (from Jul 31, 2026): 11.45 TWD.
What is the quality score of 7575?
Amed Co., Ltd. has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Amed Co., Ltd. (7575)?
Our model-based price target is the fair value of 13.41 TWD (as of Sep 24, 2026) from 17 valuation models. Cautious scenario 13.41 TWD, optimistic scenario 17.43 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Amed Co., Ltd. stock forecast for 2026?
Our models put fair value at 13.41 TWD, about +17% upside versus the last price from Jul 31, 2026 of 11.45 TWD (undervalued). Cautious scenario 13.41 TWD, optimistic scenario 17.43 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Amed Co., Ltd. (7575)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Amed Co., Ltd. it is 13.41 TWD per share (as of Sep 24, 2026), against a price of 11.45 TWD. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Amed Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 7575 trades below its calculated fair value: price 11.45 TWD, fair value 13.41 TWD, a gap of about +17% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7575?
No. The price is what the market pays today (11.45 TWD); the fair value is what the company's own numbers justify (13.41 TWD). For Amed Co., Ltd. the two are 1.96 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Amed Co., Ltd. worth?
The market values Amed Co., Ltd. at about 344M TWD (market capitalisation, as of Sep 24, 2026). Per share that is 11.45 TWD; our models calculate a fair value of 13.41 TWD per share.
What do the bullish and bearish scenarios say about 7575?
Our models span a range for Amed Co., Ltd.: cautious scenario 13.41 TWD, base 13.41 TWD, optimistic 17.43 TWD per share (as of Sep 24, 2026, price 11.45 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 7575?
Amed Co., Ltd. trades at a price-to-earnings ratio of 9.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 13.41 TWD is built from several models across several years. Other multiples: EV/EBITDA 1.7.
How solid is the balance sheet of Amed Co., Ltd. (7575)?
Balance-sheet figures for Amed Co., Ltd. (as of Sep 24, 2026): debt of 0.72 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 7575 from its 52-week high?
Amed Co., Ltd. trades at 11.45 TWD, about 62% below its 52-week high of 30.00 TWD and 14% above the low of 10.05 TWD (as of Jul 31, 2026). Distance from the high says nothing about value: that is what the fair value of 13.41 TWD is for.
Which stocks are comparable to Amed Co., Ltd.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Amed Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 11.45 TWD, calculated fair value 13.41 TWD (+17%), Quality Score 46/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7575 calculated?
We run Amed Co., Ltd. through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 13.41 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Amed Co., Ltd. currently trades 15 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Amed Co., Ltd. (7575)?
The latest price we hold is from Jul 31, 2026 and stands at 11.45 TWD. Our model-based fair value is 13.41 TWD, about +17% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Amed Co., Ltd. right now?
The price is below even our cautious bear case (13.41 TWD). The market is more pessimistic than our downside scenario. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Amed Co., Ltd.

How large is the market capitalisation of Amed Co., Ltd. (7575)?
The market capitalisation of Amed Co., Ltd. is 344M TWD (≈ $10.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Amed Co., Ltd. (7575)?
The price-to-sales ratio of Amed Co., Ltd. is 0.42 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Amed Co., Ltd. (7575)?
Earnings per share at Amed Co., Ltd. are 1.19 TWD (price ÷ EPS = P/E 9.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Amed Co., Ltd. (7575)?
The net margin of Amed Co., Ltd. is 4.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Amed Co., Ltd. (7575)?
On an EBIT basis the return on assets of Amed Co., Ltd. is 10.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Amed Co., Ltd. (7575) generate?
The free cash flow of Amed Co., Ltd. is −8.3M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Amed Co., Ltd. (7575) carry?
The net debt of Amed Co., Ltd. is 454M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Amed Co., Ltd. in the live analysis

One click puts Amed Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.